{
    "nct_id": "NCT00006399",
    "title": "Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2009-01-13",
    "description_brief": "The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.",
    "description_detailed": "Estrogen (EST) may have significant benefits in preserving cognitive functioning in normal aging after menopause and in decreasing the incidence of Alzheimer's disease (AD). On a molecular level, EST has effects on a variety of cholinergic neuronal and receptor-mediated mechanisms that may be responsible for these beneficial effects. These neurons have critical relevance for the development of age-related cognitive changes and dementing disorders. However, little is known about the clinical relevance of EST-cholinergic interactions, either in normal aging or in AD.\n\nThe primary goal of this study is to test the hypothesis that three months of administration of EST to 1) normal post-menopausal women, and 2) female patients with mild-moderate AD who are concurrently treated with anticholinesterase therapy (donepezil), will positively change or blunt the negative and behavioral effects of drugs that block central cholinergic receptors (both muscarinic and nicotinic). Participants will be blindly placed on EST or placebo for three months each. After each three month period, they will be cognitively assessed after receiving single doses of the cholinergic antagonists scopolamine and mecamylamine. These results will have direct implications for the use of EST in post-menopausal women as well as interactive treatment with cholinergic drugs for AD. Researchers plan to recruit a total of 45 women (30 healthy, and 15 patients with AD).\n\nNOTE: This study is only recruiting participants with Alzheimer's Disease at this time.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Estrogen (17\u03b2-estradiol / estrogen replacement therapy)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests administration of estrogen to post\u2011menopausal women and women with mild\u2013moderate Alzheimer\u2019s disease specifically to enhance memory and learning (i.e., improve cognitive performance rather than directly targeting amyloid or tau pathology). \ue200cite\ue202turn0search0\ue201",
        "Act (key details extracted): The study description and trial record identify 'estrogen' as the intervention and state participants receive estrogen or placebo for three months; in related published work the estrogen used is 17\u03b2\u2011estradiol (1 mg oral in a comparable randomized crossover study). The protocol includes anticholinergic challenge (scopolamine, mecamylamine) and, in the AD subgroup, concurrent anticholinesterase therapy (donepezil) to probe cholinergic effects. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results / sources (selected):\n- Trial summary: 'Effects of Estrogen on Memory in Post\u2011Menopausal Women and Patients With Alzheimer\u2019s Disease' (NCT00006399) \u2014 trial goal, design, estrogen vs placebo, anticholinergic challenge, donepezil co\u2011treatment. \ue200cite\ue202turn0search0\ue201\n- PubMed randomized challenge study: 'Estrogen treatment effects on anticholinergic\u2011induced cognitive dysfunction in normal postmenopausal women' (reports 1 mg 17\u03b2\u2011estradiol, crossover design, scopolamine/mecamylamine challenges). \ue200cite\ue202turn0search3\ue201\n- Reviews on estrogen and cholinergic neurons/ memory: literature describing estrogen\u2019s interaction with cholinergic systems and potential memory effects (mechanistic support). \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Classification as 'cognitive enhancer' aligns with the trial\u2019s stated intent and mechanism: estrogen is being tested to improve memory/learning via modulation of cholinergic function rather than as a biologic targeting Alzheimer\u2019s core pathology (amyloid/tau). Estrogen is a small steroid hormone (not a monoclonal antibody or vaccine), and the trial\u2019s endpoints and challenge design focus on cognitive performance \u2014 therefore 'cognitive enhancer' is the best fit. Sources cited above support these points. \ue200cite\ue202turn0search0\ue202turn0search3\ue202turn0search4\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The intervention is estrogen (17\u03b2\u2011estradiol / hormone replacement therapy), a steroid hormone given to improve cognition by modulating cholinergic function rather than by directly targeting amyloid or tau pathology. This aligns with CADRO\u2019s Hormones/Growth Factors domain. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Key details from the trial record and related publications show the study administered 17\u03b2\u2011estradiol (commonly 1 mg oral in comparable randomized crossover studies) versus placebo with anticholinergic challenge (scopolamine, mecamylamine) and, in the AD subgroup, concurrent anticholinesterase therapy \u2014 supporting that the biological focus is hormonal modulation of cholinergic systems to enhance cognition. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search8\ue201",
        "Reflect: Classification as L) Growth Factors and Hormones is appropriate because the drug is a hormone (estrogen) whose presumed mechanism in this trial is modulation of neural/cholinergic function and cognition, not direct modification of core AD proteinopathies (amyloid or tau). Supporting preclinical and human imaging/behavioral studies show estradiol affects cholinergic innervation and anticholinergic-challenge outcomes, reinforcing the hormone-category assignment. Alternative categories (e.g., D) Neurotransmitter Receptors) are less specific here because the intervention is a hormone acting on multiple systems rather than a selective cholinergic receptor drug. \ue200cite\ue202turn0search7\ue202turn0search5\ue201",
        "Web search results (selected sources used):",
        "- Trial summary / registry (NCT00006399) \u2014 Effects of Estrogen on Memory in Post\u2011Menopausal Women and Patients With Alzheimer\u2019s Disease. \ue200cite\ue202turn0search0\ue201",
        "- Randomized anticholinergic-challenge study describing 1 mg 17\u03b2\u2011estradiol crossover design and attenuation of some anticholinergic impairments. \ue200cite\ue202turn0search1\ue201",
        "- fMRI study showing estradiol altered anticholinergic-related brain activation during working memory. \ue200cite\ue202turn0search8\ue201",
        "- Preclinical evidence that 17\u03b2\u2011estradiol enhances cortical cholinergic innervation and preserves synaptic density in animal models. \ue200cite\ue202turn0search7\ue201",
        "- Large clinical trial findings on hormone therapy and cognition (Women's Health Initiative Memory Study) for context on cognitive outcomes with estrogen \u00b1 progestin in older women. \ue200cite\ue202turn0search9\ue201"
    ]
}